Is Biogen (BIIB) overvalued or fairly valued?

MarketChacha shows Biogen's valuation in context — a forward P/E of about 12.2, a price-to-book of about 1.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of Biogen (BIIB)?

Biogen last traded at $200.86 (-1.1% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Biogen

BIIB · NASDAQ · Healthcare · United States

$200.86-1.1%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 5:37 PM

Snapshot

TickerBIIB

ExchangeNASDAQ

SectorHealthcare

IndustryDrug Manufacturers - General

CountryUnited States

Employees7,500

HeadquartersCambridge, United States

Market cap$29.7B

P/B1.6

Volume223.09K

Websitewww.biogen.com

Filings tracked0

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.2%
Institutions96.4%
Public & other3.4%

1,451 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.10.82%
Primecap Management Company10.00%
FMR, LLC8.68%
Vanguard Capital Management LLC6.46%
State Street Corporation4.86%
Vanguard Portfolio Management LLC4.42%
Geode Capital Management, LLC2.94%
Wellington Management Group, LLP2.01%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

What's expected next

Next quarter

Rev $2.6B · EPS 2.54

Est. earnings growth -47.1%

Next fiscal year

Rev $10.3B · EPS 16.46

Est. earnings growth +35.3%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$124.5652-wk range$219.72

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Ask MarketChacha about BIIB

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.